Molina Healthcare, Inc. (MOH) Stock Analysis and Metrics

Molina Healthcare

NYSE: MOH

$197.46 ▼ -2.82 (-1.41%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap10.44 Bn

P/E54.34

P/S0.24

Div. Yield0.00

ROIC (Qtr)0.01

Total Debt (Qtr)3.77 Bn

Revenue Growth (1y) (Qtr)-4.84

Add ratio to table…

About

Molina Healthcare Inc provides managed healthcare services under Medicaid Medicare and state insurance marketplaces. The company was founded in 1980 as a provider organization serving low income families in Southern California and reincorporated in Delaware in 2002. As of December 31 2025 Molina Healthcare Inc served approximately 5.5 million members across 21 states. The firm is listed as a FORTUNE 500 company and its mission is to improve the health and lives of its members by delivering high quality health care. Its vision is to be recognized as the low cost most effective and reliable health plan delivering government sponsored care.

The company generates revenue primarily from premium payments received for managing care for members in government sponsored programs. Premiums are paid on a per member per month basis and reflect the agreed rate for each line of business and risk profile. In addition to premium revenue the firm earns modest amounts from administrative services and investment income. In 2025 premium revenue totaled 43,052 million dollars and total revenue reached 45,426 million dollars. The Medicaid Medicare Marketplace and Other segments together account for essentially all of the company's income.

The company operates through the following segments Medicaid Medicare Marketplace and Other. Each segment corresponds to a distinct government sponsored program or related activity and has its own revenue and membership base. The segments are reported separately to provide clarity on the drivers of performance.

• The Medicaid segment provides managed care services to low income individuals and families through programs such as TANF ABD CHIP Medicaid Expansion and LTSS. It contracts with state agencies to deliver comprehensive benefits including physician visits hospital care pharmacy and long term supports. In 2025 the segment generated premium revenue of 32,240 million dollars representing about 75 percent of consolidated premium revenue. The segment served approximately 4,568,000 members as of December 31 2025.

• The Medicare segment offers Medicare Advantage plans Dual Eligible Special Needs Plans and other Medicare products to seniors and disabled individuals. It includes offerings such as MAPD D SNP HIDE FIDE CO D SNP C SNP and MMP plans that coordinate care and provide supplemental benefits. In 2025 the segment generated premium revenue of 6,235 million dollars and served approximately 262,000 members. The segment emphasizes care coordination for dual eligible beneficiaries and aims to improve outcomes while managing costs.

• The Marketplace segment offers Affordable Care Act compliant health plans through state and federal exchanges. Plans are organized by metal tiers including Bronze Silver Gold and Platinum and are designed to limit out of pocket expenses for enrollees. In 2025 the segment generated premium revenue of 4,487 million dollars and served about 655,000 members. The segment operates in many states where the firm also provides Medicaid coverage allowing members to maintain provider relationships when moving between programs.

• The Other segment includes long term services and supports consultative services in Wisconsin and the commercial portion of the ConnectiCare acquisition. It also holds minor investments in health care related ventures that are not core to the firm's strategy. In 2025 the segment generated premium revenue of 90 million dollars and is described as insignificant to consolidated results. The segment's activities are limited in scope and do not materially affect overall financial performance.

Molina Healthcare Inc holds a strong position as a pure play provider of government sponsored health plans competing with larger diversified managed care organizations such as Centene Corporation CVS Health Corporation and Elevance Health Inc. The company's focus on Medicaid Medicare and Marketplace allows it to develop deep expertise in programs that serve low income and vulnerable populations. Its advantages include a strong record of winning state procurement bids and a broad and deep provider network and consistent investment in quality improvement initiatives. The firm maintains numerous NCQA accreditations across its Medicaid and Marketplace plans and seeks to achieve high Medicare Star Ratings to qualify for bonus payments. Molina Healthcare Inc invests in artificial intelligence and data analytics to improve claims processing utilization management and member engagement. These capabilities help the company operate with low administrative expenses and maintain competitive margins in a highly regulated environment.

The company serves Medicaid eligible low income individuals Medicare eligible seniors and disabled persons and consumers purchasing coverage through state and federal insurance marketplaces. Its Medicaid members include families children pregnant women elderly disabled individuals and those receiving long term supports. Medicare members consist of seniors aged sixty five and older as well as younger disabled individuals who qualify for Medicare benefits. Marketplace enrollees are primarily low income individuals who receive premium tax credits to make coverage affordable. Specific state customers include California New York Texas Washington and Wisconsin where the firm holds significant contracts. The ConnectiCare acquisition added approximately 140,000 members in Connecticut across Marketplace Medicare and commercial lines. Additionally the firm provides services to federal agencies such as the Centers for Medicare and Medicaid Services which administers the premium payments and regulatory oversight.

Investment Thesis

▲ Bull case

Molina Healthcare's embedded earnings represent a significant and underappreciated catalyst for future growth, with the Florida CMS Kids contract alone providing a $6 billion revenue run-rate that management confirmed will translate into meaningful earnings contributions starting in 2027. The company explicitly identified $2.50 per share of embedded earnings from the combination of exiting MAPD losses and Florida CMS implementation costs, both of which are expected to become positive in 2027. Despite this clear pathway to earnings accretion, management maintained a cautious stance by reaffirming 2026 guidance at "at least $5" without upward revision, even as they acknowledged modestly favorable medical cost trends and off-cycle rate increases in several states. This disconnect between the tangible near-term catalysts embedded in their contract wins and the conservative guidance suggests the market is underestimating the speed and magnitude of earnings recovery post-2026, particularly as the drag from MAPD exits lapses and Florida CMS ramps to full contribution. The upcoming Investor Day is positioned to detail margin expansion pathways through 2029, but the current failure to reflect these embedded earnings in near-term guidance creates a valuation gap where the stock does not yet price in the inflection point in earnings power that begins in 2027 and accelerates through 2029, especially given the company's history of realizing intrinsic value from franchise-building initiatives over the past eight years.
The Medicaid segment, despite facing increased attrition guidance of 6% (up from 2%), presents a bullish case due to the company's confidence that acuity shifts from pandemic-related redeterminations are fully behind them, eliminating a key historical drag on profitability. Management repeatedly emphasized that low and no utilizers are now at levels below pre-pandemic baselines, with the CEO stating the acuity shift trend experienced in 2025 is "holding up" and would not recur, supported by the CFO's analysis showing stayer-leaver ratios now align with portfolio averages. This structural improvement in risk profile means the 6% attrition assumption is primarily a volume issue, not a deterioration in mix, and crucially, the associated revenue loss is expected to be offset by strength in the Marketplace segment where renewing members now represent 70% of the book and the company remains focused on the stable silver tier (50% mix). Furthermore, states continue to provide off-cycle and retro rate updates as they did in 2025, which management cited as a source of potential guidance upside, yet these were not incorporated into the reaffirmed 2026 outlook despite being described as ongoing and favorable. The market appears to be overemphasizing the headline attrition number while underappreciating the improved risk profile and the likelihood of additional rate relief that could flip Medicaid from a drag to a neutral or even positive contributor to earnings in the latter half of 2026 and beyond.
Medicare's strategic pivot toward dual-eligible products (D-SNP, HIDE, FIDE) represents a hidden catalyst that is not yet reflected in current valuations, with early performance significantly exceeding internal expectations despite being only one quarter old. The CEO highlighted the transition of 80,000 MMP members and over $2 billion of revenue to these new integrated products as a "positive surprise" that performed "a lot better out of the gate than we had anticipated," while the CFO quantified the current Medicare run rate at approximately $5.5 billion with a 94% MCR, noting that the Stars profile for payment year 2027 has improved and the outlook for 2027+ is "only getting better over time." Importantly, the MAPD product exit, which is causing a $1 per share earnings drag in 2026, will be completely removed in 2027, leaving only the higher-margin duals business. The regulatory environment is actively favoring the integration of Medicaid and Medicare, and Molina's deep footprint in both segments positions it uniquely to capitalize on this trend, yet the market appears to be valuing the company based on the legacy MAPD-inclusive Medicare segment rather than the purer, higher-potential duals-focused franchise that will emerge post-2027, creating a clear undervaluation of the business's long-term competitive advantage and margin expansion potential in this critical growth area.

Molina Healthcare's embedded earnings represent a significant and underappreciated catalyst for future growth, with the Florida CMS Kids contract alone providing a $6 billion revenue run-rate that management confirmed will translate into meaningful earnings contributions starting in 2027. The company explicitly identified $2.50 per share of embedded earnings from the combination of exiting MAPD losses and Florida CMS implementation costs, both of which are expected to become positive in 2027. Despite this clear pathway to earnings accretion, management maintained a cautious stance by reaffirming 2026 guidance at "at least $5" without upward revision, even as they acknowledged modestly favorable medical cost trends and off-cycle rate increases in several states. This disconnect between the tangible near-term catalysts embedded in their contract wins and the conservative guidance suggests the market is underestimating the speed and magnitude of earnings recovery post-2026, particularly as the drag from MAPD exits lapses and Florida CMS ramps to full contribution. The upcoming Investor Day is positioned to detail margin expansion pathways through 2029, but the current failure to reflect these embedded earnings in near-term guidance creates a valuation gap where the stock does not yet price in the inflection point in earnings power that begins in 2027 and accelerates through 2029, especially given the company's history of realizing intrinsic value from franchise-building initiatives over the past eight years.
The Medicaid segment, despite facing increased attrition guidance of 6% (up from 2%), presents a bullish case due to the company's confidence that acuity shifts from pandemic-related redeterminations are fully behind them, eliminating a key historical drag on profitability. Management repeatedly emphasized that low and no utilizers are now at levels below pre-pandemic baselines, with the CEO stating the acuity shift trend experienced in 2025 is "holding up" and would not recur, supported by the CFO's analysis showing stayer-leaver ratios now align with portfolio averages. This structural improvement in risk profile means the 6% attrition assumption is primarily a volume issue, not a deterioration in mix, and crucially, the associated revenue loss is expected to be offset by strength in the Marketplace segment where renewing members now represent 70% of the book and the company remains focused on the stable silver tier (50% mix). Furthermore, states continue to provide off-cycle and retro rate updates as they did in 2025, which management cited as a source of potential guidance upside, yet these were not incorporated into the reaffirmed 2026 outlook despite being described as ongoing and favorable. The market appears to be overemphasizing the headline attrition number while underappreciating the improved risk profile and the likelihood of additional rate relief that could flip Medicaid from a drag to a neutral or even positive contributor to earnings in the latter half of 2026 and beyond.
Medicare's strategic pivot toward dual-eligible products (D-SNP, HIDE, FIDE) represents a hidden catalyst that is not yet reflected in current valuations, with early performance significantly exceeding internal expectations despite being only one quarter old. The CEO highlighted the transition of 80,000 MMP members and over $2 billion of revenue to these new integrated products as a "positive surprise" that performed "a lot better out of the gate than we had anticipated," while the CFO quantified the current Medicare run rate at approximately $5.5 billion with a 94% MCR, noting that the Stars profile for payment year 2027 has improved and the outlook for 2027+ is "only getting better over time." Importantly, the MAPD product exit, which is causing a $1 per share earnings drag in 2026, will be completely removed in 2027, leaving only the higher-margin duals business. The regulatory environment is actively favoring the integration of Medicaid and Medicare, and Molina's deep footprint in both segments positions it uniquely to capitalize on this trend, yet the market appears to be valuing the company based on the legacy MAPD-inclusive Medicare segment rather than the purer, higher-potential duals-focused franchise that will emerge post-2027, creating a clear undervaluation of the business's long-term competitive advantage and margin expansion potential in this critical growth area.

▼ Bear case

Molina Healthcare's reaffirmed 2026 guidance of "at least $5" in adjusted EPS masks significant near-term headwinds that the market is ignoring, particularly the accelerating Medicaid membership attrition now forecasted at 6% annually (up from 2%), which management admitted is driven by disproportionate losses in key states including California, Illinois, New York, and Texas, with California's undocumented immigrant population being a specific catalyst. While the company claims offsetting strength in Marketplace, the segment's membership is expected to decline from 305,000 at quarter-end to only 250,000 by year-end, reflecting a 18% drop that undermines the narrative of marketplace strength as a reliable counterweight. More critically, the Medical Care Ratio (MCR) guidance for Medicaid was raised to 92.9% for the full year, incorporating only a 4% rate increase against a 5% medical cost trend assumption, implying a 100 basis point margin compression before considering any additional cost pressures, and management explicitly stated they are not calling the quarterly trend of "better than 5%" for the full year due to continued volatility from the 2025 medical cost inflection environment, suggesting the 5% trend assumption may prove optimistic if historical patterns of accelerating costs resurface.
The company's debt metrics present an underappreciated risk that contradicts management's comfort with current leverage, with debt at 6.1x trailing EBITDA and a debt-to-capital ratio of 48%, significantly above their long-term target in the low 40% range, and this leverage is being sustained despite only modest operating cash flow conversion. Although operating cash flow was $1.1 billion in the quarter, the CFO admitted this was largely driven by government payment timing and emphasized that only parent-level cash (currently $213 million) is meaningful for redeployment, with a target of exceeding $600 million by year-end via subsidiary dividends—a target that remains uncertain given the need to maintain subsidiary RBC ratios above $300 million. This creates a potential liquidity constraint where growth initiatives or M&A activity, which management described as having a "quite replete" pipeline, could be hampered if parent cash accumulation falls short, especially as the company continues to invest in high-cost implementations like the Florida CMS Kids contract without a clear path to deleveraging, making the balance sheet more vulnerable to any downturn in medical cost trends or reimbursement delays than management acknowledges.
The Florida CMS Kids contract, while touted as a $6 billion revenue run-rate and a meaningful addition to embedded earnings, introduces substantial execution and margin risks that are being overlooked in the bullish narrative, with management acknowledging that new business typically comes in at a "pretty high MCR in its first quarter" and the CFO noting the contract requires "some lumpy expenses quarter-to-quarter" as they gear up for this "very large contract." The scale of the initiative—equivalent to nearly 15% of the company's current $42 billion premium revenue guidance—means any stumble in implementation, whether due to behavioral health cost overruns (which the company admits is a "very large component" of the program), provider network challenges, or state-level payment delays, could disproportionately impact consolidated results. Furthermore, the contribution to embedded earnings is contingent on successful ramp-up, and while management expects it to be positive in 2027, they offered no specifics on timing or magnitude beyond the $2.50 per share figure tied to 2026 implementation costs, leaving open the risk that the financial benefits are delayed or muted, particularly if the company's historically strong behavioral health cost management fails to scale effectively in this new, complex population.

Molina Healthcare's reaffirmed 2026 guidance of "at least $5" in adjusted EPS masks significant near-term headwinds that the market is ignoring, particularly the accelerating Medicaid membership attrition now forecasted at 6% annually (up from 2%), which management admitted is driven by disproportionate losses in key states including California, Illinois, New York, and Texas, with California's undocumented immigrant population being a specific catalyst. While the company claims offsetting strength in Marketplace, the segment's membership is expected to decline from 305,000 at quarter-end to only 250,000 by year-end, reflecting a 18% drop that undermines the narrative of marketplace strength as a reliable counterweight. More critically, the Medical Care Ratio (MCR) guidance for Medicaid was raised to 92.9% for the full year, incorporating only a 4% rate increase against a 5% medical cost trend assumption, implying a 100 basis point margin compression before considering any additional cost pressures, and management explicitly stated they are not calling the quarterly trend of "better than 5%" for the full year due to continued volatility from the 2025 medical cost inflection environment, suggesting the 5% trend assumption may prove optimistic if historical patterns of accelerating costs resurface.
The company's debt metrics present an underappreciated risk that contradicts management's comfort with current leverage, with debt at 6.1x trailing EBITDA and a debt-to-capital ratio of 48%, significantly above their long-term target in the low 40% range, and this leverage is being sustained despite only modest operating cash flow conversion. Although operating cash flow was $1.1 billion in the quarter, the CFO admitted this was largely driven by government payment timing and emphasized that only parent-level cash (currently $213 million) is meaningful for redeployment, with a target of exceeding $600 million by year-end via subsidiary dividends—a target that remains uncertain given the need to maintain subsidiary RBC ratios above $300 million. This creates a potential liquidity constraint where growth initiatives or M&A activity, which management described as having a "quite replete" pipeline, could be hampered if parent cash accumulation falls short, especially as the company continues to invest in high-cost implementations like the Florida CMS Kids contract without a clear path to deleveraging, making the balance sheet more vulnerable to any downturn in medical cost trends or reimbursement delays than management acknowledges.
The Florida CMS Kids contract, while touted as a $6 billion revenue run-rate and a meaningful addition to embedded earnings, introduces substantial execution and margin risks that are being overlooked in the bullish narrative, with management acknowledging that new business typically comes in at a "pretty high MCR in its first quarter" and the CFO noting the contract requires "some lumpy expenses quarter-to-quarter" as they gear up for this "very large contract." The scale of the initiative—equivalent to nearly 15% of the company's current $42 billion premium revenue guidance—means any stumble in implementation, whether due to behavioral health cost overruns (which the company admits is a "very large component" of the program), provider network challenges, or state-level payment delays, could disproportionately impact consolidated results. Furthermore, the contribution to embedded earnings is contingent on successful ramp-up, and while management expects it to be positive in 2027, they offered no specifics on timing or magnitude beyond the $2.50 per share figure tied to 2026 implementation costs, leaving open the risk that the financial benefits are delayed or muted, particularly if the company's historically strong behavioral health cost management fails to scale effectively in this new, complex population.

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	384.70 Bn	30.02	0.90	77.92 Bn
2	CVS	CVS HEALTH Corp	136.05 Bn	46.86	1.84	63.11 Bn
3	ELV	Elevance Health, Inc.	82.25 Bn	16.64	0.45	31.04 Bn
4	CI	Cigna Group	75.16 Bn	11.50	0.75	30.90 Bn
5	HUM	Humana Inc	47.47 Bn	38.91	0.46	13.99 Bn
6	CNC	Centene Corp	31.35 Bn	-4.86	0.17	16.37 Bn
7	MOH	Molina Healthcare, Inc.	10.44 Bn	54.34	0.24	3.77 Bn
8	OSCR	Oscar Health, Inc.	8.62 Bn	-218.95	1.15	0.43 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Related and Nonrelated Parties Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password